Global cancer statistics, 2012, Global cancer statistics, pp.87-108, 2012. ,
DOI : 10.1002/ijc.29210
A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe, Annals of Oncology, vol.24, issue.6, pp.1667-1674, 2013. ,
DOI : 10.1093/annonc/mds652
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis, Gastroenterology, vol.132, issue.7, pp.2557-2576, 2007. ,
DOI : 10.1053/j.gastro.2007.04.061
The impact of antiviral therapy on the course of chronic HCV infection: A systematic review, Journal of Hepatology, vol.38, issue.3, pp.175-182, 2003. ,
DOI : 10.1016/S0168-8278(03)80689-X
Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies, Annals of Oncology, vol.25, issue.8, 2014. ,
DOI : 10.1093/annonc/mdu020
Population-based risk factors and resource utilization for HCC: US perspective, Current Medical Research and Opinion, vol.26, issue.9, pp.2183-2191, 2010. ,
DOI : 10.1185/03007995.2010.506375
Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma, Clinics in Liver Disease, vol.19, issue.2, pp.361-379, 2015. ,
DOI : 10.1016/j.cld.2015.01.012
Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis, Diabetes/Metabolism Research and Reviews, vol.282, issue.11, 2012. ,
DOI : 10.1002/dmrr.1291
Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis, The American Journal of Gastroenterology, vol.30, issue.6, pp.881-91, 2013. ,
DOI : 10.1038/ajg.2013.5
Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies, British Journal of Cancer, vol.55, issue.7, pp.1005-1008, 2007. ,
DOI : 10.1016/j.gastro.2004.09.018
Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives, Gastroenterology, vol.125, issue.6, pp.1733-1741, 2003. ,
DOI : 10.1053/j.gastro.2003.09.035
Primary biliary cirrhosis and cancer risk: A systematic review and meta-analysis, Hepatology, vol.50, issue.4, pp.1409-1417, 2012. ,
DOI : 10.1002/hep.25788
Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies, World J Gastroenterol, 2013. ,
Systematic review of randomized trials for ,
Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes, Gastroenterology, vol.138, issue.1, pp.52-64, 2010. ,
DOI : 10.1053/j.gastro.2009.09.006
Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology, vol.140, issue.2, pp.497-507, 2011. ,
DOI : 10.1053/j.gastro.2010.10.049
Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma, Liver Cancer, vol.4, issue.1, 2015. ,
DOI : 10.1159/000367728
Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization, Acta Radiologica, vol.49, issue.5, pp.523-529, 2008. ,
DOI : 10.1080/02841850801958890
Comparison of Hypoxia-inducible Factor-1?? Expression before and after Transcatheter Arterial Embolization in Rabbit VX2 Liver Tumors, Journal of Vascular and Interventional Radiology, vol.19, issue.10, pp.1483-1489, 2008. ,
DOI : 10.1016/j.jvir.2008.06.017
Chemoembolization for Hepatocellular Carcinoma, Seminars in Oncology, vol.39, issue.4, 2012. ,
DOI : 10.1053/j.seminoncol.2012.05.004
URL : https://hal.archives-ouvertes.fr/hal-01134844
Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis, Journal of Cancer Research and Clinical Oncology, vol.9, issue.2, pp.1429-1440, 2014. ,
DOI : 10.1007/s00432-014-1684-5
Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study, European Radiology, vol.33, issue.6, pp.1214-1223, 2012. ,
DOI : 10.1007/s00330-011-2368-z
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial, International Journal of Cancer, vol.15, issue.6, pp.1458-1467, 2015. ,
DOI : 10.1002/ijc.29126
Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival, European Radiology, vol.39, issue.8, pp.1719-1726, 2011. ,
DOI : 10.1007/s00330-011-2118-2
Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics, Journal of Hepatology, vol.46, issue.3, pp.474-481, 2007. ,
DOI : 10.1016/j.jhep.2006.10.020
Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis, CardioVascular and Interventional Radiology, vol.23, issue.6, pp.1119-1128, 2012. ,
DOI : 10.1007/s00270-012-0394-0
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines, Journal of Hepatology, vol.56, issue.4, pp.886-892, 2012. ,
DOI : 10.1016/j.jhep.2011.10.021
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study, Liver International, vol.38, issue.Suppl 1, 2015. ,
DOI : 10.1111/liv.12818
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treatment Reviews, vol.37, issue.3, pp.212-220, 2011. ,
DOI : 10.1016/j.ctrv.2010.07.006
URL : https://hal.archives-ouvertes.fr/hal-01134844
Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia, Oncology, vol.81, issue.s1, pp.158-164, 2011. ,
DOI : 10.1159/000333280
Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients, Gastroenterology, vol.131, issue.2, pp.461-469, 2006. ,
DOI : 10.1053/j.gastro.2006.05.021
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution, Hepatology, vol.167, issue.Suppl, 1998. ,
DOI : 10.1002/hep.510270617
Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes, Surgical Oncology Clinics of North America, vol.12, issue.1, pp.105-126, 2003. ,
DOI : 10.1016/S1055-3207(02)00089-3
Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence, Journal of Surgical Oncology, vol.43, issue.2, pp.109-114, 2000. ,
DOI : 10.1002/(SICI)1096-9098(200002)73:2<109::AID-JSO10>3.0.CO;2-J
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010 Feb, pp.52-60 ,
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization, Journal of Hepatology, vol.55, issue.6, 2011. ,
DOI : 10.1016/j.jhep.2011.03.007
Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization, Journal of Hepatology, vol.58, issue.6, pp.1181-1187, 2013. ,
DOI : 10.1016/j.jhep.2013.01.039
Selective and sequential transarterial chemoembolization: Survival in patients with hepatocellular carcinoma, European Journal of Radiology, vol.81, issue.9, pp.2290-2297, 2012. ,
DOI : 10.1016/j.ejrad.2011.09.010
Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques, Hepatology, vol.365, issue.Suppl, pp.2238-2244, 2011. ,
DOI : 10.1002/hep.24670
Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment?, Radiology, vol.265, issue.1, pp.115-123, 2012. ,
DOI : 10.1148/radiol.12112264
Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, vol.53, issue.6, pp.1051-1056, 2012. ,
DOI : 10.1111/j.1440-1746.2011.06963.x
Treatment of intermediate-stage hepatocellular carcinoma, Nature Reviews Clinical Oncology, vol.32, issue.9, pp.525-535, 2014. ,
DOI : 10.1016/S0140-6736(11)61347-0
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer, Annals of Oncology, vol.24, issue.10 ,
DOI : 10.1093/annonc/mdt247
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions, Semin Liver Dis, vol.32, issue.4, pp.348-359, 2012. ,
The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma, Hepatology, vol.262, issue.Suppl 4, pp.2261-2273, 2013. ,
DOI : 10.1002/hep.26256
Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process, Journal of Hepatology, vol.62, issue.4, pp.855-862 ,
DOI : 10.1016/j.jhep.2014.11.014
How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma, Journal of Hepatology, vol.61, issue.6, pp.1287-1296, 2014. ,
DOI : 10.1016/j.jhep.2014.07.002
Role of systemic inflammatory response in predicting survival in patients with primary operable cancer, Future Oncology, vol.6, issue.1, pp.149-163, 2010. ,
DOI : 10.2217/fon.09.136
Serum Creactive protein levels predict survival in hepatocellular carcinoma, Liver Int, 2007. ,
The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma, Cancer, vol.37, issue.9, pp.1856-1864, 2005. ,
DOI : 10.1002/cncr.20976
The addition of Creactive protein to validated staging systems improves their prognostic ability in patients with hepatocellular carcinoma, Oncology, vol.86, pp.5-6308, 2014. ,
Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation, Journal of Gastroenterology and Hepatology, vol.29, issue.7, pp.553-561, 2012. ,
DOI : 10.1111/j.1440-1746.2011.06910.x
Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation, World Journal of Gastroenterology, vol.19, issue.45, pp.8398-8407, 2013. ,
DOI : 10.3748/wjg.v19.i45.8398
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib, Medical Oncology, vol.7, issue.8, pp.264-278, 2014. ,
DOI : 10.1007/s12032-014-0264-5
Pretreatment Neutrophil???Lymphocyte Ratio, Medicine, vol.94, issue.11 ,
DOI : 10.1097/MD.0000000000000639
Neutrophil-to-lymphocyte and plateletto-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization, PLoS One, vol.10, issue.3, p.119312, 2015. ,
Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis, Journal of Gastroenterology and Hepatology, vol.33, issue.Suppl. 3, pp.787-793, 2014. ,
DOI : 10.1111/jgh.12452
The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE, J.Hepatol, vol.60, issue.1, pp.118-126, 2014. ,